A multicenter, retrospective study in patients with multiple sclerosis treated with natalizumab in a real-world setting in Japan: The REFIND study

The significant reduction in ARR observed with EID or SID/EID suggests that there is little difference between these dosing regimens in this retrospective dataset in Japan. The effectiveness of natalizumab in reducing the number of new or enlarging T2 lesions was similar across all dosing groups and consistent with known high efficacy of natalizumab in controlling disease activity. These real-world data on natalizumab EID in Japan may help inform treatment choices for Asian populations.

Authors

Institutions

Publication Details

Journal
Multiple Sclerosis and Related Disorders
Published
2026-01-15
DOI
https://doi.org/10.1016/j.msard.2026.107007
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A multicenter, retrospective study in patients with multiple sclerosis treated with natalizumab in a real-world setting in Japan: The REFIND study

Michihiro Kanda, Hirofumi Ochi, Fumitaka Shimizu, Jin Nakahara et al.
Multiple Sclerosis and Related Disorders
Multiple Sclerosis Research Studies
article

A multicenter, retrospective study in patients with multiple sclerosis treated with natalizumab in a real-world setting in Japan: The REFIND study

Michihiro Kanda, Hirofumi Ochi, Fumitaka Shimizu, Jin Nakahara, Nobuaki Yoshikura, Yumiko Tani, Hiroaki Yokote, Ichiro NAKASHIMA, Masahiro Mori, Toshiyuki Fukazawa, Chiyoko Nohara, Kenichi Kaida, Kazumasa Yokoyama, Noriko Isobe, Takashi Yamamura, Takayuki Kondo, Masaaki Niino, Kazuo Fujihara, Takashi Ohashi, Izumi Kawachi, Kenzo Sakurai, Yuko Shimizu
article en

Abstract

The significant reduction in ARR observed with EID or SID/EID suggests that there is little difference between these dosing regimens in this retrospective dataset in Japan. The effectiveness of natalizumab in reducing the number of new or enlarging T2 lesions was similar across all dosing groups and consistent with known high efficacy of natalizumab in controlling disease activity. These real-world data on natalizumab EID in Japan may help inform treatment choices for Asian populations.

Multiple Sclerosis and Related DisordersVol. 107
Kansai Medical University (JP), Fukushima Medical University (JP), Kyushu University (JP), Chiba University (JP), St. Marianna University School of Medicine (JP), Yamaguchi University (JP), Keio University (JP), Tokyo Metropolitan Komagome Hospital (JP), Juntendo University (JP), Sapporo Higashi Tokushukai Hospital (JP), Ebara Hospital (JP), National Hospital Organization Hokkaido Medical Center (JP), National Center of Neurology and Psychiatry (JP), Japan Bio Products (Japan) (JP), Tokyo Women's Medical University (JP), Tohoku Medical and Pharmaceutical University Hospital (JP), Gifu University (JP), Ehime University (JP), Niigata University (JP), Saitama Medical University (JP)
Good health and well-being
Openalex Percentile: Top 87%
Multiple Sclerosis Research Studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.